Clinical Trial

A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice

Study acronym: PILLAR
Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
This observational study will explore how Wegovy® (Semaglutide) is used in everyday situations, how it might affect things like weight, body mass index (BMI) and waist circumference, and what kind of impact it could have on overall quality of life. The overall purpose of this study is to understand how Wegovy impacts weight when used as part of regular medical care. Participants will be treated with Wegovy as prescribed to the participant by their doctor, in accordance with normal clinical practice. The study will last for about two years.
Protocol Amendment History 1 change
notable Trial sites expanded: 16 -> 30 locations 2026-05-15
Trial Details
NCT Number NCT07055607
Lead Sponsor Novo Nordisk A/S
Conditions Obesity
Enrollment 1,250 participants
Start Date 2025-05-01
Primary Completion 2028-08-15 (estimated)
Study Completion 2028-08-15 (estimated)
Updated on ClinicalTrials.gov 2026-08-04